TICARCILLIN

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H16N2O6S2
Molecular Weight	384.427
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O

InChI

InChIKey=OHKOGUYZJXTSFX-KZFFXBSXSA-N

InChI=1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C15H16N2O6S2
Molecular Weight	384.427
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2387996 | https://www.drugs.com/pro/ticar.html

Ticarcillin (also known as Ticar) is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. Ticarcillin is not absorbed orally; therefore, it must be given intravenously or intramuscularly. Ticarcillin's antibiotic properties arise from its ability to prevent cross-linking of peptidoglycan during cell wall synthesis when the bacteria tries to divide, causing death. Usage of ticar was discontinued.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2387996	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Sepsis 74 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8583	TICAR Approved Use Unknown Launch Date 1976
Skin and soft tissue infections 33 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8583	TICAR Approved Use Unknown Launch Date 1976
Acute and chronic respiratory tract infections 6 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8583	TICAR Approved Use Unknown Launch Date 1976
Intra-abdominal infections 50 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8583	TICAR Approved Use Unknown Launch Date 1976
Infections of the female pelvis and genital tract 6 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8583	TICAR Approved Use Unknown Launch Date 1976

C_max

Value	Dose	Co-administered	Analyte	Population
576.2 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
621.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
431.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
324 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
747 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
890 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
538 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
485 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
339 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	50 mg/kg bw single, intravenous dose: 50 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
74.8 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
84.7 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
80.7 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
76 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140806/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	50 mg/kg bw single, intravenous dose: 50 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4073101	unhealthy, 19-91 Health Status: unhealthy Age Group: 19-91 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4073101	Disc. AE: Rash, Nausea... Other AEs: Elevated liver enzymes, Eosinophilia... AEs leading to discontinuation/dose reduction: Rash (grade 1, 2.7%) Nausea (grade 2, 2.7%) Other AEs: Elevated liver enzymes Eosinophilia Sources: https://pubmed.ncbi.nlm.nih.gov/4073101
80 mg/kg single, intravenous Highest studied dose Dose: 80 mg/kg Route: intravenous Route: single Dose: 80 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/3777901	healthy, 22-26 Health Status: healthy Age Group: 22-26 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3777901	Sources: https://pubmed.ncbi.nlm.nih.gov/3777901
3 g 5 times / day multiple, intravenous Overdose Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	Other AEs: Convulsions... Other AEs: Convulsions Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf
3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	Other AEs: Hypersensitivity reaction, Diarrhea, Clostridium difficile... Other AEs: Hypersensitivity reaction (grade 3-5) Diarrhea, Clostridium difficile Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf

AEs

AE	Significance	Dose	Population
Elevated liver enzymes		3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4073101	unhealthy, 19-91 Health Status: unhealthy Age Group: 19-91 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4073101
Eosinophilia		3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4073101	unhealthy, 19-91 Health Status: unhealthy Age Group: 19-91 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4073101
Rash	grade 1, 2.7% Disc. AE	3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4073101	unhealthy, 19-91 Health Status: unhealthy Age Group: 19-91 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4073101
Nausea	grade 2, 2.7% Disc. AE	3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4073101	unhealthy, 19-91 Health Status: unhealthy Age Group: 19-91 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4073101
Convulsions		3 g 5 times / day multiple, intravenous Overdose Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf
Diarrhea, Clostridium difficile		3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf
Hypersensitivity reaction	grade 3-5	3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
UGT2B15 84 ALDH 8 OAT1 725 OAT2 153 OATP1B3 961

Drug as perpetrator

Target	Modality	Activity
ALDH 8	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
OAT2 155	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
OATP1B3 970	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
UGT2B15 84	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
OAT1 730	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	yes [IC50 1833 uM]

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:9587	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9587
ChemicalBook	CB7224768	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7224768
eMolecules	29537804	https://www.emolecules.com/cgi-bin/more?vid=29537804
ZINC	ZINC000003831540	http://zinc15.docking.org/substances/ZINC000003831540

PubMed

Title	Date	PubMed
Acinetobacter baumanii folliculitis in a patient with AIDS.	2005-05	15807684
Natural antimicrobial susceptibility patterns and biochemical identification of Escherichia albertii and Hafnia alvei strains.	2005-03	15766600
Inquilinus limosus in patients with cystic fibrosis, Germany.	2005-03	15757565
Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.	2005-03	15737511
Antimicrobial resistance of selected Salmonella isolates from food animals and food in Alberta.	2005-02	15825516
Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas.	2005-01	15710671
Antimicrobial susceptibility of bifidobacteria.	2005-01	15574479
[Pseudomonas aeruginosa: a multicentric study of antibiotic resistance (1999-2000)].	2004-12	15822507
[Infectious cellulitis and Shewanella alga septicemia in an immunocompetent patient].	2004-12	15692446
Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci.	2004-12	15573053
Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males.	2004-09	15561650
CTX-M beta-lactamase-producing Escherichia coli in long-term care facilities, France.	2004-09	15503413
Resistance to beta-lactam antibiotics in Aeromonas hydrophila isolated from rainbow trout (Oncorhynchus mykiss).	2004-09	15492935
Antibiotic susceptibility patterns among respiratory isolates of Gram-negative bacilli in a Turkish university hospital.	2004-08-22	15320954
A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.	2004-08	15289131
Detection and assay of beta-lactamases in clinical and non-clinical strains of Yersinia enterocolitica biovar 1A.	2004-08	15269194
The value of a CT-guided fine needle aspirate in infants with lung abscess.	2004-08	15265191
[A 4-year study of Pseudomonas aeruginosa susceptibility to antibiotics (1998-2001) in northern Lebanon].	2004-07	15679237
Clinical significance of Roseomonas species isolated from catheter and blood samples: analysis of 36 cases in patients with cancer.	2004-06-01	15156446
[Carbapenemase detection in Acinetobacter baumannii clones resistant to imipenem].	2004-05	15207116
An epidemiological analysis of Stenotrophomonas maltophilia strains in a university hospital.	2004-04	15118205
Comparative activity of beta-lactam agents (carbapenem excepted) against Pseudomonas aeruginosa strains with CARB or OXA beta-lactamases.	2004-04	15084803
Antibiotic resistance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice.	2004-03	14986156
Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.	2004-02	14729755
Detection of an IS21 insertion sequence in the mexR gene of Pseudomonas aeruginosa increasing beta-lactam resistance.	2004-01-15	14734177
[Surveillance on antibiotic resistance of Stenotrophomonas maltophilia in Chengdu and Chongqing area].	2004-01	14981826
[Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].	2004	15773503
[Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].	2004	15700687
Detection of ticarcillin-clavulonic acid susceptibility with microdilution method in Citrobacter, Hafnia, Proteus and some gram negative bacteria.	2004	15508433
[Management of ENT diseases complications using ticarcillin clavulanate].	2004	15134082
Antimicrobial susceptibility and synergistic activity of meropenem against Gram-negative non-fermentative bacteria isolated from cystic fibrosis patients.	2003-12	14998078
[Enterobacterial susceptibility to antibiotics in northern Lebanon (1998-2001)].	2003-10-08	14530123
[Antibiotic resistance of Acinetobacter baumannii isolates: data from Ibni Sina Hospital for the year 2002].	2003-10	14748260
Haemorrhagic cystitis with ticarcillin: risk factors include cystic fibrosis.	2003-10	14619904
Natural antibiotic susceptibility of Ewingella americana strains.	2003-10	14598935
[Which betalactam antibiotic use as a marker of multiresistance in Pseudomonas aeruginosa?].	2003-10	14568590
Natural antimicrobial susceptibilities and biochemical profiles of Yersinia enterocolitica-like strains: Y. frederiksenii, Y. intermedia, Y. kristensenii and Y. rohdei.	2003-09-22	13129648
Simultaneous determination of ticarcillin and clavulanate in rabbit serum and tissue cage fluid by liquid chromatography.	2003-09-05	12954375
Early antibiotic selection and efficient rooting and acclimatization improve the production of transgenic plum plants (Prunus domestica L.).	2003-08	12827433
[Community-acquired Pseudomonas aeruginosa bacteremic pneumonia in a "healthy" subject].	2003-07-12	12947742
[Phenotypes of beta-lactam resistance in the genus Aeromonas].	2003-07	14567197
Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii.	2003-07	12842326
Ticarcillin-clavulanic acid plus amikacin versus ceftazidime plus amikacin in the empirical treatment of fever in acute leukemia: a prospective randomized trial.	2003-06	12868552
Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients.	2003-06	12796602
Sequence analysis and biochemical characterisation of chromosomal CAV-1 (Aeromonas caviae), the parental cephalosporinase of plasmid-mediated AmpC 'FOX' cluster.	2003-05-16	12757951
Application of MEKC for determination of ticarcillin and clavulanic acid in Timentin intravenous preparation.	2003-04-24	12852449
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma.	2003-04	12959681
Efficiency of procedures for induction and cultivation of Pseudomonas syringae pv. pisi L-form.	2003	14717447
Beta-lactamase characterization in Escherichia coli isolates with diminished susceptibility or resistance to extended-spectrum cephalosporins recovered from sick animals in Spain.	2003	12820806
Epitope analysis of aztreonam by antiaztreonam monoclonal antibodies and possible consequences in beta-lactams hypersensitivity.	1992	1384868

Patents

Sample Use Guides

In Vivo Use Guide

Bacterial septicemia: 200 to 300 mg/kg/day by I.V. infusion in divided doses every 4 or 6 hours. Respiratory tract infections: (The usual dose is 3 grams given every 4 hours [18 grams/day] or 4 grams given every 6 hours [16 grams/day] depending on weight and the severity of the infection.) Urinary tract infections: Complicated: 150 to 200 mg/kg/day by I.V. infusion in divided doses every 4 or 6 hours. (Usual recommended dosage for average [70 kg] adults: 3 grams q.i.d.) Uncomplicated: 1 gram I.M. or direct I.V. every 6 hours.

Route of Administration: Other

In Vitro Use Guide

A total of 632 clinical bacterial isolates were tested for susceptibility to twofold dilutions of ticarcillin alone and in combination with 1, 2, and 4 micrograms of clavulanic acid (CA) (Timentin) per ml by a reference microdilution method. With the addition of CA, ticarcillin MICs were reduced eightfold or greater with 54 of 59 (92%) strains of the family Enterobacteriaceae with ticarcillin MICs of greater than or equal to 64 micrograms/ml. Ticarcillin MICs for beta-lactamase-producing Haemophilus influenzae, Neisseria gonorrhoeae, and most Staphylococcus aureus were reduced to less than or equal to 0.5 micrograms/ml when CA was added.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:39:49 GMT 2025` Edited by `admin` on `Wed Apr 02 09:39:49 GMT 2025`
Record UNII	F93UJX4SWT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TICARCILLIN [MI]

Preferred Name

English

TICARCILLIN

Official Name

English

ticarcillin [INN]

Common Name

English

Ticarcillin [WHO-DD]

Common Name

English

4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 6-(((2R)-2-CARBOXY-2-(3-THIENYL)ACETYL)AMINO)-3,3-DIMETHYL-7-OXO-, (2S,5R,6R)-

Common Name

English

TICARCILLIN [VANDF]

Common Name

English

(2S,5R,6R)-6-(((2R)-2-CARBOXY-2-(3-THIENYL)ACETYL)AMINO)-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID

Systematic Name

English

Classification Tree Code System Code

NDF-RT

N0000011281